Item | 6m 2024 | 6m 2025 | Change |
---|---|---|---|
Revenues | 5,095.03 | 6,542.11 | 28.4 % |
Gross Income | 1,755.36 | 2,094.29 | 19.3 % |
Operating Income | 1,107.75 | 1,270.79 | 14.7 % |
Net Income | 1,105.97 | 1,148.03 | 3.8 % |
Average Shares | 350.00 | 350.00 | - |
Earnings Per Share before unusual items (Riyals) | 3.16 | 3.28 | 3.8 % |
EPS (Riyal) | 3.16 | 3.28 | 3.8 % |
EBITDA increased by 22.73% to SAR 1.67 billion, pushing up EBITDA margin to 25.59%.
As part of its ongoing growth strategy, the group launched several new hospitals across key regions. In 2024, operations commenced at Al-Fayhaa Hospital (Jeddah), Shamal Al Riyadh Hospital (Riyadh), and Women's Health Hospital (Riyadh). Expansion continued in 2025 with the operational openings of Al-Hamra Hospital (Riyadh), Al-Kharj Hospital (Al-Kharj), and Al Muhammadiyah Hospital (Jeddah).
These newly launched facilities are in their initial ramp-up phase, with revenue contributions expected to accelerate as each hospital approaches optimal operating capacity.
Item | Q2 2024 | Q2 2025 | Change |
---|---|---|---|
Revenues | 2,573.62 | 3,384.33 | 31.5 % |
Gross Income | 878.03 | 1,065.98 | 21.4 % |
Operating Income | 551.67 | 644.87 | 16.9 % |
Net Income | 555.03 | 591.02 | 6.5 % |
Average Shares | 350.00 | 350.00 | - |
Earnings Per Share before unusual items (Riyal) | 1.59 | 1.69 | 6.5 % |
EPS (Riyal) | 1.59 | 1.69 | 6.5 % |
Item | Q1 2025 | Q2 2025 | Change |
---|---|---|---|
Revenues | 3,157.78 | 3,384.33 | 7.2 % |
Gross Income | 1,028.31 | 1,065.98 | 3.7 % |
Operating Income | 625.93 | 644.87 | 3.0 % |
Net Income | 557.01 | 591.02 | 6.1 % |
Average Shares | 350.00 | 350.00 | - |
Earnings Per Share before unusual items (Riyal) | 1.59 | 1.69 | 6.1 % |
EPS (Riyal) | 1.59 | 1.69 | 6.1 % |
Q2 2025 net profit grew 6% to SAR 591 million, compared to SAR 555.03 million in the year-earlier period.
On a quarterly basis, net earnings rose 6.1% from SAR 557.01 million in Q1 2025.
Total shareholders’ equity, excluding minority interest, reached SAR 7.49 billion by June 30, 2025, compared to SAR 6.79 billion in the prior-year period.
Company | Estimated | Actual | Change |
---|---|---|---|
NADEC | 116.50 | 115.26 | (1.1 %) |
ARDCO | 47.00 | 65.63 | 28.4 % |
YANSAB | 57.72 | 44.50 | (29.7 %) |
SABIC AGRI-NUTRIENTS | 948.04 | 1,060.00 | 10.6 % |
ZAIN KSA | 110.10 | 127.00 | 13.3 % |
MODERN MILLS | 48.78 | 49.67 | 1.8 % |
SOLUTIONS | 392.70 | 446.00 | 12.0 % |
SULAIMAN ALHABIB | 588.80 | 591.02 | 0.4 % |
TADAWUL GROUP | 112.77 | 96.25 | (17.2 %) |
SADAFCO | 130.00 | 117.66 | (10.5 %) |
Company | Estimated | Actual | Change |
---|---|---|---|
NADEC | 116.50 | 115.26 | (1.1 %) |
ARDCO | 47.00 | 65.63 | 28.4 % |
YANSAB | 57.72 | 44.50 | (29.7 %) |
SABIC AGRI-NUTRIENTS | 948.04 | 1,060.00 | 10.6 % |
ZAIN KSA | 110.10 | 127.00 | 13.3 % |
MODERN MILLS | 48.78 | 49.67 | 1.8 % |
SOLUTIONS | 392.70 | 446.00 | 12.0 % |
SULAIMAN ALHABIB | 588.80 | 591.02 | 0.4 % |
TADAWUL GROUP | 112.77 | 96.25 | (17.2 %) |
SADAFCO | 130.00 | 117.66 | (10.5 %) |
Be the first to comment
Argaam Investment Company has updated the Privacy Policy of its services and digital platforms. Know more about our Privacy Policy here.
Argaam uses cookies to personalize content, to provide social media features and analyze traffic, that we might also share with third parties. You consent to our cookies if you use this website
Comments Analysis: